Stocktoria
PharmaCyte Biotech, Inc. PMCB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2003-09-11
PharmaCyte Biotech, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $438,416 | $407,431 | $468,536 | $690,937 | $916,249 |
| Operating income | -$4.4M | -$8.5M | -$6.5M | -$4.4M | -$3.6M |
| Interest expense | — | — | $0 | $509 | $3,046 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | $30.7M | $333,763 | -$4.3M | -$4.2M | -$3.6M |
| EPS (diluted) | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-2.45 |
| Operating cash flow | -$3.0M | -$2.2M | -$3.8M | -$4.1M | -$3.3M |
| Cash & equivalents | $15.2M | $50.2M | $68.0M | $85.4M | — |
| Total assets | $55.2M | $59.9M | $73.3M | $90.6M | $7.4M |
| Total liabilities | $3.3M | $20.4M | $586,581 | $704,370 | $724,778 |
| Shareholders' equity | $51.9M | $27.6M | $72.7M | $89.9M | $6.7M |
Source: SEC EDGAR filings · CIK 0001157075 · as of 2025-04-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.